ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.33−0.09 (-0.79%)
Close on Nov 17, 2026Market cap $102.90MP/E 141.6Yield –
ImmuCell pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
ImmuCell's pe ratio was 127.4× on Nov 11, 2026, against 729.0× a year earlier. Over the last 5 years it ranged from 15.7× to 899.0×, with a median of 52.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 127.4× | +103.7 |
| 2025 | Dec 31, 2025 | 23.7× | −777.3 |
| 2022 | Oct 31, 2022 | 801.0× | +1.0 |
| 2021 | Dec 31, 2021 | 800.0× | +68.0 |
| 2018 | Jan 31, 2018 | 732.0× | −147.0 |
| 2017 | Dec 29, 2017 | 879.0× | +850.7 |
| 2016 | Dec 30, 2016 | 28.3× | +5.5 |
| 2015 | Dec 31, 2015 | 22.8× | −79.7 |
| 2014 | Apr 30, 2014 | 102.5× | +49.1 |
| 2013 | Dec 31, 2013 | 53.4× | −46.6 |
| 2012 | Dec 31, 2012 | 100.0× | – |
See a number that looks wrong?